DLA
TRAW icon

Douglas Lane & Associates’s Traws Pharma TRAW Stock Holding History

Douglas Lane & Associates’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$41K – 227
2016
Q1 		$41K Buy
+1
New +$31.7K ﹤0.01% 216

Other funds holding TRAW

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Douglas Lane & Associates's TRAW Position: Q2 2016 in Review

Douglas Lane & Associates sold out of Traws Pharma (TRAW) in Q2 2016, closing a stake of 1 share — an estimated $41K sold.

Douglas Lane & Associates first reported a position in TRAW in Q1 2016 and held it in 1 quarter. The position peaked at $41K in Q1 2016. 4 funds tracked by Wall St. Rank hold TRAW as of Q2 2016.

  • Douglas Lane & Associates reported no remaining Traws Pharma position as of Q2 2016 after selling out during the quarter.
  • Douglas Lane & Associates sold 1 Traws Pharma share in Q2 2016, an estimated $41K.
  • Douglas Lane & Associates first reported a position in Traws Pharma in Q1 2016 and held it in 1 quarter.
  • Douglas Lane & Associates's Traws Pharma position peaked at $41K in Q1 2016.
  • 4 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2016.

Based on Douglas Lane & Associates's 13F filing for Q2 2016, filed 25 Jul 2016.